Main Research Findings
1) Treatment with SAM-e was found to reduce markers of depression in patients with HIV.

2) SAM-e was shown to protect hepatic cells against hypotonic hemolysis and enzyme leakage from cultured hepatocytes.

 

 

Selected Data
1) The study by Shippy and colleagues was designed to evaluate the efficacy, safety, and tolerability of S-adenosyl-L-methionine (SAM-e) as a treatment for major depressive disorder (MDD) in people living with HIV/AIDS. Depression is considerably more prevalent among individuals with HIV than in the general population and is associated with poorer medication adherence, diminished quality of life, accelerated disease progression, increased substance abuse, and higher suicide risk. Despite its high prevalence, depression remains underdiagnosed and undertreated in this population because many patients already manage complex highly active antiretroviral therapy (HAART) regimens and are reluctant to add conventional antidepressants due to concerns about additional pills, adverse effects, and potential drug interactions [1].
Previous studies had demonstrated that SAM-e possesses antidepressant properties with fewer side effects than many selective serotonin reuptake inhibitors (SSRIs), while also producing a more rapid onset of action. Because SAM-e is a naturally occurring methyl donor involved in the synthesis of neurotransmitters such as serotonin and dopamine, the investigators hypothesized that it could provide a safe and effective alternative treatment for depression in HIV-positive individuals without substantially increasing treatment burden. The primary objective of the study was therefore to determine whether oral SAM-e could rapidly reduce depressive symptoms over an eight-week treatment period while maintaining an acceptable safety profile in adults diagnosed with major depressive disorder.
Participants interested in the study first completed a structured telephone screening administered by the study coordinator using the Primary Care Evaluation of Mental Disorders (PRIME-MD) instrument to identify symptoms suggestive of depression. Individuals who screened positive were subsequently invited for an in-person psychiatric evaluation conducted by the study psychiatrist. Formal psychiatric diagnosis was established using the Structured Clinical Interview for DSM-IV (SCID-IV), ensuring that only participants meeting standardized diagnostic criteria for Major Depressive Disorder were enrolled. A total of thirty individuals completed telephone screening, twenty met all eligibility criteria and provided written informed consent, and these twenty participants comprised the final study cohort [1].
Strict inclusion and exclusion criteria were implemented to minimize potential confounding variables and maximize participant safety. Eligible participants were required to be HIV-seropositive adults with a confirmed DSM-IV diagnosis of Major Depressive Disorder. Individuals were excluded if they had unstable medical illnesses, pregnancy or lactation, recent substance abuse within the preceding month, concurrent use of psychotropic medications within two weeks before study initiation, treatment with monoamine oxidase inhibitors (MAOIs), active suicidal ideation, psychotic symptoms, reversible medical conditions believed to be responsible for depressive symptoms, or a history of mania or bipolar disorder. These criteria were intended to isolate the effects of SAM-e on primary major depression while minimizing risks associated with psychiatric instability or medication interactions. Participants received modest financial compensation of fifteen dollars for each completed study visit to encourage adherence to scheduled follow-up assessments throughout the eight-week trial [1].
Treatment consisted of oral SAM-e administered twice daily with individualized dose titration according to therapeutic response and tolerability. All participants began treatment with 200 mg of SAM-e twice daily, accompanied by daily supplementation with 1,000 μg of vitamin B12 and 800 μg of folic acid, nutrients known to support methylation pathways involved in SAM-e metabolism. Throughout the study, the dose of SAM-e was gradually increased based on each participant’s clinical response and adverse effects. Participants who experienced nausea or insomnia were not increased beyond a total daily dose of 800 mg, whereas individuals who tolerated therapy without side effects could receive doses up to 1,600 mg per day (800 mg twice daily). Dose adjustments were individualized according to symptom severity and improvement observed during follow-up visits. Clinical response was predefined as a greater than 50% reduction in depressive symptom scores measured using both clinician-administered and self-reported depression rating scales. This flexible dosing strategy allowed investigators to optimize antidepressant efficacy while minimizing treatment-related adverse effects for each participant.
Participants attended study visits at baseline and at weeks 1, 2, 4, 6, and 8 following initiation of treatment. During each visit, participants completed structured clinical interviews addressing physical symptoms, medical status, substance use, and cognitive function. Depression severity was assessed using two well-validated instruments: the Beck Depression Inventory (BDI) and the Hamilton Rating Scale for Depression (HAM-D). The BDI is a 21-item self-administered questionnaire with scores ranging from 0 to 63, where higher scores indicate greater depressive severity. Scores above 30 were classified as severe depression, scores between 10 and 30 represented moderate depression, and scores below 10 indicated minimal or absent depressive symptoms. The HAM-D is a 17-item clinician-administered scale designed specifically to measure changes in depression severity over time. HAM-D scores above 24 reflected severe depression, scores between 7 and 17 indicated mild depression, and scores below 7 were considered evidence of remission. Using both patient-reported and clinician-rated measures allowed investigators to compare subjective symptom improvement with independent psychiatric assessment throughout treatment [1].
The investigators identified two principal efficacy endpoints before beginning statistical analysis. The first compared baseline depression scores with those obtained after one week of treatment to evaluate the rapidity of antidepressant onset. Because conventional antidepressants often require several weeks before clinical improvement becomes apparent, demonstrating significant improvement after only one week would represent an important therapeutic advantage. The second primary comparison evaluated changes between baseline and week eight, reflecting sustained treatment efficacy over the full duration of the trial. To determine the consistency of patient- and clinician-reported outcomes, BDI and HAM-D scores were standardized using Z-score transformations and compared statistically. Mean depression scores at each study visit were analyzed using paired t-tests, allowing investigators to determine whether changes from baseline reached statistical significance. In addition, an intent-to-treat analysis was performed using the last observation carried forward for all participants who received at least one dose of SAM-e, ensuring that treatment efficacy could be evaluated even among individuals who did not complete the entire study [1].
2) The study by Tsuji and colleagues was designed to investigate the membrane-protective properties of S-adenosyl-L-methionine (SAM-e) by examining its ability to reduce cellular injury in two complementary experimental models: hypotonic hemolysis of rat erythrocytes and enzyme leakage from primary cultured rat hepatocytes. Previous clinical and experimental studies had demonstrated that SAM-e plays a central role in biological methylation reactions, serves as the primary methyl donor for numerous biochemical processes, and exerts therapeutic effects in conditions such as intrahepatic cholestasis and depression [2].
More recent evidence suggested that SAM-e could increase liver plasma membrane fluidity and stimulate Na⁺,K⁺-ATPase activity, raising the possibility that it may stabilize cellular membranes and protect against membrane damage. Because disruption of membrane integrity is a common feature of many liver disorders and other pathological conditions, the investigators sought to determine whether SAM-e directly protects cell membranes from injury. Specifically, they compared two commercially available salt forms of SAM-e: S-adenosyl-L-methionine disulfate tosylate (SAMe-ST) and S-adenosyl-L-methionine chloride (SAMe-Cl), to determine whether the protective activity resided in the SAM-e molecule itself or in one of its associated salt components. The effects of SAM-e were also compared with those of L-methionine (L-Met), the metabolic precursor of SAM-e, to determine whether conversion to SAM-e was necessary for optimal membrane protection.
Experiments were performed using adult male Sprague-Dawley rats weighing approximately 170 grams. All chemicals used in the investigation were of analytical grade, and the two salt forms of SAM-e were supplied by Sankyo Co., Ltd. For the erythrocyte experiments, blood cells were isolated from rats and suspended in a standardized hypotonic phosphate-buffered saline solution designed to produce approximately fifty percent hemolysis under control conditions. This well-established experimental model provides a sensitive measure of membrane stability because osmotic stress causes rupture of erythrocyte membranes and release of intracellular hemoglobin. The investigators incubated erythrocyte suspensions containing varying concentrations of either SAMe-ST, SAMe-Cl, or L-methionine ranging from 0.01 to 5.0 mg/mL for one hour at 37°C. After incubation, the samples were centrifuged, and the concentration of free hemoglobin released into the supernatant was measured spectrophotometrically at 540 nm. The amount of extracellular hemoglobin served as a quantitative index of membrane rupture and hypotonic hemolysis, allowing investigators to compare the membrane-protective effects of each compound across a broad concentration range [2].
To evaluate membrane protection in liver cells, primary hepatocyte cultures were established using a modified version of Seglen’s collagenase perfusion technique. Rat livers were perfused through the portal vein with calcium- and magnesium-free Hanks’ balanced salt solution containing EGTA and HEPES buffer to remove blood and disrupt cell-cell adhesions. This initial perfusion was followed by recirculation with a collagenase-containing buffer supplemented with calcium chloride to digest extracellular matrix proteins and liberate hepatocytes. Following enzymatic digestion, the liver tissue was gently dispersed, filtered through a 150-μm mesh, and centrifuged to isolate hepatocytes. The cells were resuspended in Williams’ E medium supplemented with fetal bovine serum, insulin, dexamethasone, penicillin, streptomycin, and fungizone to promote survival and growth under sterile culture conditions. Cell viability was assessed using the trypan blue exclusion test, which demonstrated viability ranging from 90% to 98%, confirming successful isolation of healthy hepatocytes suitable for experimentation. Hepatocytes were then plated at a density of approximately one million cells per milliliter onto plastic culture dishes and maintained as monolayer cultures in a humidified incubator containing 5% carbon dioxide at 37°C. The culture medium was replaced after three hours, and cells were allowed to stabilize for an additional twenty-one hours before experimental treatments were initiated.
Following establishment of stable hepatocyte cultures, investigators evaluated the effects of SAMe-ST and L-methionine on membrane integrity by measuring the leakage of intracellular enzymes into the culture medium. Hepatocytes were exposed to varying concentrations of either compound ranging from 0.1 to 1.0 mg/mL for an additional twenty-four hours. After treatment, the culture medium was collected and analyzed for several intracellular enzymes commonly used as indicators of hepatocellular injury. These included glutamic-oxaloacetic transaminase (GOT; AST), glutamic-pyruvic transaminase (GPT; ALT), ornithine carbamyl transferase (OCT), and lactate dehydrogenase (LDH). Leakage of these enzymes into the extracellular medium reflects disruption of plasma membrane integrity and cellular injury. GOT and GPT activities were determined using the colorimetric method of Ohkawa and colleagues, OCT activity was measured according to the method of Ceriotti, and LDH activity was quantified using the Babson and Phillips procedure. Comparing enzyme leakage among treatment groups enabled investigators to determine whether SAM-e protected hepatocyte membranes from spontaneous injury during prolonged culture [2].
Because previous studies suggested that SAM-e influences membrane-associated enzymes, the investigators also examined the effects of treatment on Na⁺,K⁺-ATPase activity, a critical membrane enzyme responsible for maintaining ionic gradients and normal cellular function. Following twenty-four hours of treatment with either 1.0 mg/mL SAMe-ST or 1.0 mg/mL L-methionine, hepatocyte membranes were isolated for enzymatic analysis. Na⁺,K⁺-ATPase activity was measured using the method of Pressley and colleagues in the presence of 3 mM ouabain, which selectively inhibits Na⁺,K⁺-ATPase and allows accurate determination of enzyme-specific activity. Enzymatic function was quantified by measuring the amount of inorganic phosphate released during ATP hydrolysis using the Goldenberg and Fernandez colorimetric assay. Total protein concentrations were determined by the Bradford method using bovine serum albumin as the reference standard, allowing ATPase activity to be normalized per milligram of protein. This analysis provided mechanistic insight into whether improvements in membrane stability were associated with enhanced membrane enzyme function.
Throughout the investigation, careful comparisons were made between the different forms of SAM-e and L-methionine to distinguish the biological activity of the SAM-e molecule itself from any potential effects of its accompanying salt forms or metabolic precursor. Initial erythrocyte experiments compared both SAMe-ST and SAMe-Cl directly to determine whether sulfate, tosylate, or chloride ions contributed to membrane protection. Once similar activity was demonstrated for both preparations, subsequent hepatocyte experiments focused exclusively on the more stable SAMe-ST formulation together with L-methionine. This experimental strategy allowed the investigators to determine not only whether SAM-e protected cellular membranes but also whether direct administration of SAM-e produced greater protection than administration of its metabolic precursor [2].

 

Discussion
1) The study by Shippy et al demonstrated that SAM-e produced rapid, substantial, and sustained improvements in depressive symptoms among people living with HIV/AIDS who had been diagnosed with Major Depressive Disorder. Across both clinician-administered and self-reported depression assessments, participants experienced significant reductions in depression severity beginning within the first week of treatment and continuing throughout the entire eight-week study period. By the conclusion of the trial, the majority of participants achieved both clinical response and remission while experiencing very few adverse effects. These findings suggest that SAM-e is a well-tolerated antidepressant with an unusually rapid onset of action, making it a potentially valuable treatment option for HIV-positive individuals who may be reluctant to initiate conventional antidepressant medications because of concerns regarding additional medication burden and adverse effects [1].
The study enrolled twenty HIV-seropositive adults diagnosed with Major Depressive Disorder, of whom fifteen completed the full eight-week treatment protocol. The participant population consisted primarily of middle-aged adults, with a median age of forty-five years, and included both men and women from diverse racial and ethnic backgrounds. Five participants discontinued the study before completion. Two participants withdrew after the first week of treatment, while three additional participants discontinued participation after the fourth week. Several of these individuals had complex clinical histories, including previous injection drug use, hepatitis C co-infection, obsessive-compulsive disorder, prior suicide attempts, or advanced HIV disease meeting AIDS diagnostic criteria. Importantly, however, depression data obtained before withdrawal were incorporated into analyses evaluating the early onset of treatment response, while additional intent-to-treat analyses included all participants who had received at least one dose of SAM-e. This approach minimized the influence of participant attrition on interpretation of treatment efficacy [1].
One of the most important findings of the investigation was the exceptionally rapid antidepressant effect observed following initiation of SAM-e therapy. Significant improvements in depressive symptoms were already evident after only one week of treatment. Self-reported depression measured using the Beck Depression Inventory (BDI) declined dramatically from a baseline mean score of 33.5, representing severe depression, to 18.9 after one week of treatment. This reduction was highly statistically significant and represented an improvement exceeding the investigators’ predefined threshold for clinical response. Similar improvements were observed using the clinician-administered Hamilton Rating Scale for Depression (HAM-D). Mean HAM-D scores decreased from 26.5 at baseline, reflecting severe depression, to 16.8 after only one week of treatment, a statistically significant reduction. Both assessment instruments therefore demonstrated that participants experienced more than a 50% reduction in depressive symptoms within the first week of therapy. This rapid onset distinguishes SAM-e from many conventional antidepressants, which often require several weeks before clinically meaningful improvements become apparent.
Depression scores continued to improve steadily throughout the remainder of the study. Among the fifteen participants who completed the full eight-week treatment period, mean BDI scores progressively declined from 35.1 at baseline to 14.1 at week two, 8.8 at week four, 6.4 at week six, and finally 5.1 at week eight. By the conclusion of treatment, average BDI scores had fallen into the range indicating minimal or absent depressive symptoms. This overall reduction from baseline to week eight was highly statistically significant (p < 0.001). The HAM-D demonstrated a nearly identical pattern of improvement. Mean clinician-rated depression scores decreased from 26.7 at baseline to 10.7 at week two, 6.0 at week four, 5.2 at week six, and 3.7 by week eight. These results showed continuous improvement throughout treatment rather than a transient early response, indicating that the antidepressant effects of SAM-e were sustained over time. Graphical analyses presented in the study illustrated a consistent downward trajectory in both BDI and HAM-D scores across every assessment point, with no evidence of symptom worsening during follow-up [1].
The magnitude of clinical improvement translated into exceptionally high remission and response rates among participants who completed treatment. Using the investigators’ predefined criteria, remission was defined as a HAM-D score of 7 or lower, while clinical response required at least a 50% reduction in HAM-D score relative to baseline. Fourteen of the fifteen participants who completed the study (93%) achieved remission by week eight, while the remaining participant improved substantially but retained a HAM-D score of 13, slightly above the remission threshold. Similarly, fourteen of fifteen participants (93%) achieved the predefined criterion for treatment response. These remission rates compare favorably with those reported for many conventional antidepressant therapies and suggest that SAM-e was highly effective among individuals who completed the treatment protocol.
The investigators also performed an intent-to-treat analysis, which included all twenty participants who initiated therapy regardless of whether they completed the study. This more conservative analysis yielded results that closely paralleled those observed among study completers. Mean BDI scores declined from 33.5 at baseline to 6.6 using each participant’s last available assessment, while HAM-D scores decreased from 26.5 to 7.7. Both reductions remained highly statistically significant. Even after accounting for participant withdrawals, the overall remission rate remained 79%, with fifteen of twenty participants achieving HAM-D scores of seven or less. Likewise, the clinical response rate remained 74%, with fourteen of nineteen evaluable participants demonstrating at least a 50% reduction in depression severity. These findings indicate that the observed antidepressant effects were robust and not solely attributable to participants who completed the full treatment course [1].
Another important finding involved the close agreement between participant self-assessments and clinician ratings of depression. Statistical comparisons demonstrated no significant differences between BDI and HAM-D evaluations at any study visit. This consistency indicates that patients’ subjective perceptions of symptom improvement closely matched the independent assessments performed by trained psychiatrists. The concordance between these two validated instruments strengthens confidence that the observed reductions in depression reflected genuine clinical improvement rather than bias associated with either self-report or clinician evaluation alone. The consistency of findings across both measurement methods provides strong evidence supporting the antidepressant efficacy of SAM-e in this population.
Overall, the investigators concluded that SAM-e is a safe, well-tolerated, and rapidly acting antidepressant for people living with HIV/AIDS. The significant reductions in both self-reported and clinician-rated depression scores, the high remission and response rates, and the minimal incidence of adverse effects all support its potential utility as an alternative treatment for depression in this medically complex population. The authors noted that the unusually rapid onset of clinical improvement may be related to the pharmacokinetics of SAM-e, as previous research has shown that serum concentrations peak within twenty-four hours of administration. Nevertheless, they acknowledged several important limitations, including the open-label design, absence of a placebo control group, lack of blinding, and relatively small sample size. Consequently, although the findings strongly support the antidepressant potential of SAM-e, the investigators recommended that larger randomized, double-blind, placebo-controlled clinical trials be conducted to confirm these encouraging preliminary results and further establish the role of SAM-e in treating depression among people living with HIV/AIDS [1].
2) The study by Tsuji et al demonstrated that SAM-e exerts pronounced membrane-protective effects in both erythrocytes and primary cultured hepatocytes. Across multiple experimental models, SAM-e significantly reduced cell membrane damage, inhibited hypotonic hemolysis, decreased leakage of intracellular enzymes associated with hepatocellular injury, and enhanced membrane-associated Na⁺,K⁺-ATPase activity. Importantly, the protective effects were attributable to the SAM-e molecule itself rather than the sulfate, tosylate, or chloride salt forms used for drug formulation. Although L-methionine, the metabolic precursor of SAM-e, exhibited modest protective effects in several experiments, its efficacy was consistently inferior to that of SAM-e and, at higher concentrations, it occasionally produced detrimental effects. Collectively, these findings support the hypothesis that SAM-e directly stabilizes biological membranes and protects cells against injury through mechanisms involving alterations in membrane structure and function rather than simply serving as a precursor for endogenous methylation pathways [2].
The first series of experiments examined the effects of SAM-e on hypotonic hemolysis of rat erythrocytes, a well-established model of membrane fragility. Under control conditions, exposure of erythrocytes to the hypotonic buffer produced approximately 50% hemolysis, providing a sensitive baseline for evaluating membrane stabilization. Both SAMe-ST and SAMe-Cl significantly protected erythrocytes from osmotic rupture over a concentration range of 0.2 to 2.0 mg/mL. The degree of protection produced by the two salt forms was nearly identical throughout the effective concentration range, indicating that neither the sulfate-tosylate nor chloride components contributed to the observed biological activity. Instead, the investigators concluded that the membrane-protective effects resided entirely within the SAM-e moiety itself. Protection increased progressively with increasing concentrations of SAM-e until an optimal range was reached. At concentrations above approximately 2.0 mg/mL, the protective effect gradually diminished, suggesting that membrane stabilization occurs within an optimal concentration window rather than increasing indefinitely with dose. These findings demonstrated that SAM-e directly strengthens erythrocyte membranes and reduces susceptibility to osmotic injury.
In contrast, L-methionine displayed substantially weaker protective activity during the hemolysis experiments. At a concentration of approximately 1.0 mg/mL, L-methionine produced only a modest reduction in hemolysis compared with untreated controls. Unlike SAM-e, increasing the concentration of L-methionine beyond this level failed to improve protection. Instead, higher concentrations actually produced a slight increase in erythrocyte hemolysis, suggesting that excessive L-methionine may adversely affect membrane stability under osmotic stress. The markedly different dose-response relationship observed between SAM-e and its metabolic precursor demonstrated that direct administration of SAM-e provides considerably greater membrane protection than administration of L-methionine alone. This finding also suggested that conversion of L-methionine into endogenous SAM-e may be insufficient to reproduce the immediate membrane-stabilizing effects achieved through direct SAM-e supplementation [2].

 

Figure 1: Changes in hypotonic hemolysis of rat erythrocytes following treatment with SAM-e.
The hepatocyte experiments yielded similarly favorable results. Following twenty-four hours of incubation, untreated cultured hepatocytes released measurable amounts of intracellular enzymes into the culture medium as a consequence of spontaneous membrane injury occurring during prolonged culture. Treatment with SAMe-ST significantly reduced leakage of GOT/AST compared with untreated controls. Significant reductions were observed at concentrations of 0.5 and 1.0 mg/mL, demonstrating improved preservation of hepatocyte membrane integrity. In contrast, treatment with L-methionine failed to significantly reduce GOT leakage and produced enzyme activities that remained comparable to untreated control cultures. Because GOT leakage is widely recognized as a sensitive indicator of hepatocellular membrane damage, these findings provided strong evidence that SAM-e effectively protects liver cell membranes against injury [2].
A similar pattern was observed for OCT, another intracellular enzyme released following hepatocellular injury. SAMe-ST treatment produced highly significant reductions in OCT leakage across effective dose ranges, indicating preservation of membrane integrity and reduced cellular damage. The magnitude of OCT reduction was greater than that observed for several of the other enzymes measured, suggesting that SAM-e provided broad protection against hepatocyte injury. By comparison, L-methionine produced little or no measurable improvement in OCT leakage, with enzyme activities remaining close to those observed in untreated control cultures. These findings further reinforced the conclusion that direct administration of SAM-e provides substantially greater hepatocellular protection than administration of its metabolic precursor.
Analysis of GPT/ALT demonstrated that both compounds exerted some protective activity, although the effects of SAM-e remained superior. Treatment with SAMe-ST significantly reduced GPT leakage at all tested concentrations, with the highest dose producing the greatest degree of protection. L-methionine also reduced GPT leakage, but the reductions were consistently smaller than those observed with SAM-e. Thus, although L-methionine exhibited partial protective activity in this particular assay, direct administration of SAM-e remained substantially more effective at maintaining hepatocyte membrane integrity. The investigators interpreted these findings as additional evidence that the membrane-stabilizing properties of SAM-e exceed those expected from simply increasing methionine availability.
The results obtained for LDH were particularly informative because they highlighted important differences between the two compounds. SAMe-ST consistently reduced LDH leakage throughout the concentration range studied, indicating reduced cytoplasmic enzyme loss and improved preservation of membrane integrity. L-methionine produced modest reductions in LDH leakage at lower concentrations of 0.1 and 0.5 mg/mL, but the highest concentration (1.0 mg/mL) unexpectedly caused a marked increase in LDH release that exceeded control values. Because LDH is a highly sensitive marker of membrane disruption and cellular injury, the investigators suggested that excessive concentrations of L-methionine may exert unfavorable effects on hepatocyte membranes despite modest protective actions at lower doses. In contrast, SAM-e continued to demonstrate protective effects without evidence of toxicity at comparable concentrations, further emphasizing its superior membrane-stabilizing properties [2].
The mechanistic experiments examining Na⁺,K⁺-ATPase activity provided important insight into the potential basis of SAM-e’s protective effects. Both SAMe-ST and L-methionine increased Na⁺,K⁺-ATPase activity in cultured hepatocytes compared with untreated controls. However, the increase produced by SAMe-ST was substantially greater than that observed following L-methionine treatment. Because Na⁺,K⁺-ATPase is an essential membrane-bound enzyme responsible for maintaining transmembrane ionic gradients, its enhanced activity suggests improved membrane function and structural integrity. Previous studies had shown that phospholipid methylation influences membrane fluidity and ATPase activity, and the present findings support the hypothesis that SAM-e promotes favorable alterations in membrane phospholipid composition that enhance enzyme function while stabilizing cellular membranes. The investigators proposed that increased membrane fluidity resulting from phospholipid methylation may improve membrane protein function and thereby protect cells from mechanical and biochemical injury [2].

 

Figure 2: Effects of SAM-e on NA+, K+, and ATPase activity in cultured rat hepatocytes.
Overall, the investigators concluded that SAM-e is a potent membrane-protective agent capable of reducing both erythrocyte hemolysis and hepatocyte injury through direct effects on membrane structure. The comparable activity observed with both SAMe-ST and SAMe-Cl demonstrated that the protective actions originate from the SAM-e molecule itself rather than its associated salts. Based on the reduction in enzyme leakage, inhibition of hemolysis, and stimulation of Na⁺,K⁺-ATPase activity, the authors proposed that the primary site of action of SAM-e is the cell membrane, where it likely enhances membrane fluidity, phospholipid turnover, and membrane protein function through transmethylation-dependent mechanisms. They concluded that these membrane-stabilizing properties may underlie the previously reported clinical benefits of SAM-e in liver disease and suggested that preservation of membrane integrity represents an important mechanism by which SAM-e protects cells from injury [2].

 

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

 

Citations

[1] Shippy RA, Mendez D, Jones K, Cergnul I, Karpiak SE. S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS. BMC Psychiatry. 2004;4:38. Published 2004 Nov 11. doi:10.1186/1471-244X-4-38

[2] Tsuji M, Kodama K, Oguchi K. Protective effect of S-adenosyl-L-methionine against CCl4-induced hepatotoxicity in cultured hepatocytes. Jpn J Pharmacol. 1990;52(2):209-214. doi:10.1254/jjp.52.209

 

SAM-e (S-Adenosyl-L-methionine Disulfate Tosylate) is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.